Figure 1From: High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility studyComplete response in patient with mediastinal lymphopaty and bowel metastases treated in Cohort A (schedule d1,8-28).Back to article page